Search
Mipicoledine
go.drugbank.com/drugs/DB15075InvestigationalMipicoledine is under investigation in clinical trial NCT01048008 (Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer).
Categories: P-glycoprotein substratesUpadacitinib
go.drugbank.com/drugs/DB15091ApprovedInvestigationalUpadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmu...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsTepotinib
go.drugbank.com/drugs/DB15133ApprovedInvestigationalTepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid tumors. It was originally developed in partnership between EMD Serono and the University of Texas M.D. Anderson Cancer Center in 2009 an...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesDeutivacaftor
go.drugbank.com/drugs/DB15141ApprovedInvestigationalDeutivacaftor is a small molecule cystic fibrosis transmembrane conductance regulator (CFTR) potentiator. It is used alongside CFTR correctors to increase the quantity and function of CFTR at the cell surface in patients with cystic fibr...
Categories: Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C9 InhibitorsAvapritinib
go.drugbank.com/drugs/DB15233ApprovedInvestigationalAvapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mast...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesBrensocatib
go.drugbank.com/drugs/DB15638ApprovedNon-cystic fibrosis bronchiectasis (NCFB) is a chronic lung disease characterized by airway widening, mucus accumulation, and neutrophilic inflammation. Brensocatib is a first-in-class dipeptidyl peptidase 1 (DPP1) inhibitor that inhibit...
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A InducersBerotralstat
go.drugbank.com/drugs/DB15982ApprovedInvestigationalBerotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic pe...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesAtogepant
go.drugbank.com/drugs/DB16098ApprovedInvestigationalAtogepant is an oral antagonist of calcitonin gene-related peptide (CGRP) receptors indicated for the prevention of episodic migraine headaches. It was developed by AbbVie and received FDA approval under the brand name Qulipta in Septemb...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesLazertinib
go.drugbank.com/drugs/DB16216ApprovedInvestigationalLazertinib is an oral, third-generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of EGFR T790M mutation-positive non-sma...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsAlmonertinib
go.drugbank.com/drugs/DB16640ApprovedInvestigationalAlmonertinib is a third-generation EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M resistance mutations. Unlike other third-generation EGFR TKIs, almonertinib is a pyrimidine-based drug that forms a covalent bond to t...
Categories: P-glycoprotein inhibitors, P-glycoprotein substrates